Novel Molecular Classification of Breast Cancer with PET Imaging DOI Creative Commons
Ngô Minh Toàn

Medicina, Journal Year: 2024, Volume and Issue: 60(12), P. 2099 - 2099

Published: Dec. 21, 2024

Breast cancer is a heterogeneous disease characterized by wide range of biomarker expressions, resulting in varied progression, behavior, and prognosis. While traditional biopsy-based molecular classification the gold standard, it invasive limited capturing tumor heterogeneity, especially deep or metastatic lesions. Molecular imaging, particularly positron emission tomography (PET) offering non-invasive alternative, potentially plays crucial role management breast providing detailed information about location, progression. This narrative review, which focuses on both clinical patients preclinical studies, explores latest advancements PET imaging for cancer, emphasizing development new tracers targeting hormone receptors such as estrogen alpha receptor, progesterone androgen beta well ErbB family receptors, VEGF/VEGFR, PARP1, PD-L1, markers indirectly assessing Ki-67. These innovative radiopharmaceuticals have potential to guide personalized treatment approaches based unique profiles individual patients. Additionally, they may improve assessment efficacy, ultimately leading better outcomes those diagnosed with cancer.

Language: Английский

A Meta-Analysis Studying the Difference in Response to Trastuzumab–Deruxtecan Based on HER2 Immunohistochemistry Staining in HER2 Low Metastatic Breast Cancer Patients DOI
Prashanth Ashok Kumar, Michael Sandhu, Devashish Desai

et al.

American Journal of Therapeutics, Journal Year: 2025, Volume and Issue: unknown

Published: April 29, 2025

Language: Английский

Citations

0
Comprehensive Assessment of Immune Phenotype and Its Effects on Survival Outcomes in HER2-Low versus HER2-Zero Breast Cancer DOI Creative Commons
Heidi Ko, R. J. Seager, Sarabjot Pabla

et al.

Breast Cancer Targets and Therapy, Journal Year: 2024, Volume and Issue: Volume 16, P. 483 - 495

Published: Aug. 1, 2024

The understanding of molecular characteristics HER2-low breast cancer is evolving since the establishment trastuzumab deruxtecan. Here, we explore differences in expression patterns immune-related genes tumor immune microenvironment (TME) and survival between HER2-zero cancers.

Language: Английский

Citations

2
Unsung oral toxicities of antibody drug conjugate DOI
Prazwala Chirravur

Oral Oncology, Journal Year: 2024, Volume and Issue: 150, P. 106692 - 106692

Published: Jan. 25, 2024

Language: Английский

Citations

1
Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer DOI Creative Commons
Valentina Guarneri,

José Luís Passos Coelho,

François P. Duhoux

et al.

Future Oncology, Journal Year: 2024, Volume and Issue: 20(18), P. 1237 - 1250

Published: April 9, 2024

Trastuzumab deruxtecan (T-DXd) is approved for the treatment of human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer (mBC). Results on T-DXd in HER2-low mBC have so far been limited to clinical trials. DESTINY-Breast Respond Europe (NCT05945732) a multi-center, multi-country, observational, prospective, non-interventional study planning enroll 1350 patients from 216 sites receiving or conventional chemotherapy as their routine care advanced stage 12 European countries. This will provide real-world insight into with data effectiveness, safety and tolerability, patient-reported outcomes, patterns, geriatric health status HER2 testing. be beneficial improving guidance maximize patient benefit.

Language: Английский

Citations

1
Characterization of HER2-Low Breast Tumors among a Cohort of Colombian Women DOI Open Access
Laura Rey-Vargas, Lina María Bejarano-Rivera, Diego Felipe Ballén

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(18), P. 3141 - 3141

Published: Sept. 12, 2024

HER2-low tumors have shown promise in response to antibody-drug conjugates (ADCs) recent clinical trials, underscoring the need characterize this group's phenotype. In study, we aimed explore clinicopathological features, survival rates, and HER2 amplicon mRNA expression of women affected with breast cancer, compared HER2-negative HER2-positive groups. We included 516 cancer patients from Colombia, for whom three genes (

Language: Английский

Citations

1
Prognostic Impact of HER2 Low Status in Male Breast Cancer: Prospective Cohort Analysis DOI Open Access
Atanas Ignatov,

Sina Lempfer,

József Mészáros

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(19), P. 3399 - 3399

Published: Oct. 5, 2024

Male breast cancer (MBC) is a rare disease, and the potential influence of low expression human epidermal growth factor receptor 2 (HER2 low) remains unexplored.

Language: Английский

Citations

1
Antibody–drug conjugates in patients with advanced/metastatic HER2-low-expressing breast cancer: a systematic review and meta-analysis DOI Creative Commons
Isabella Michelon, Maria Inez Dacoregio, Maysa Vilbert

et al.

Therapeutic Advances in Medical Oncology, Journal Year: 2024, Volume and Issue: 16

Published: Jan. 1, 2024

Background: Until recently, targeted therapies have failed to benefit patients with human epidermal growth factor receptor 2 (HER2)-low-expressing breast cancer (BC). Nevertheless, antibody–drug conjugates (ADCs) reshaped their prognosis. Objectives: We performed a systematic review and meta-analysis assess the effectiveness of ADCs in HER2-low advanced/metastatic (a/m) BC. Design: This study is meta-analysis. Data sources: searched PubMed, Embase, Cochrane databases as well American Society Clinical Oncology, European for Medical San Antonio Breast Cancer Symposium conference proceedings. Methods: Studies evaluating (trastuzumab deruxtecan (T-DXd), sacituzumab govitecan (SG), MRG002, RC48-ADC) a/mBC were included. used R software (v.4.2.2) random effects models all analyses. Heterogeneity was assessed using I test. Results: Overall, 14 studies included (five real-world nine clinical trials (CTs)), 2883 patients: 808 received treatment physician’s choice (TPC), 2075 ADCs. Most treated T-DXd ( n = 1691), followed by SG 310), MRG002 56), RC48-ADC 18). Patients achieved significantly higher objective response rate (ORR), disease control (DCR), (CBR) than those receiving other In pooled analysis four randomized CTs, statistically prolonged progression-free survival 1828, hazard ratio (HR) 0.50, 95% confidence interval (CI) 0.36–0.68, 82%, p < 0.001) overall 1546, HR 0.70, CI 0.57–0.86, 43%, compared TPC. on also greater antitumor TPC, including better ORR (odds (OR), 3.7, 2.5–5.6, 59%, 0.001), DCR (OR, 2.7, 2.1–3.5, 0%, CBR 3.6, 2.6–5.2, 56%, 0.01). Conclusion: Our confirms efficacy a/m BC over Future should focus bringing into earlier lines therapy this population. Trial registration: registered PROSPERO (CRD42024452962).

Language: Английский

Citations

1
Impact of Neoadjuvant Therapy on PD-L1 Expression in Triple-Negative Breast Cancer and Correlation with Clinicopathological Factors DOI Creative Commons
Nevena Ilieva, Mina Pencheva,

Hristo Hadzhiev

et al.

Diagnostics, Journal Year: 2024, Volume and Issue: 14(23), P. 2672 - 2672

Published: Nov. 27, 2024

Background: This study aims to deliver more insights on the impact of neoadjuvant treatment Pd-L1 expression and evaluate its correlation with clinicopathological factors. Methods: We reviewed 88 TNBC cases for period 2021–2023. Data age, tumor size, stage, were collected. Histological slides assessed subtype, grade, TILs. A total 48 received treatment. HER2 Ki67 evaluated via immunohistochemistry. PD-L1 was tested primary residual tumors. Statistical analysis performed using IBM SPSS (p < 0.05). Results: In this study, positive found in 44.3% tumors, 52.9% initially losing post-treatment. TILs significantly higher PD-L1-positive tumors (mean 41.79% vs. 27.55%, p = 0.001). notable between Ki-67 proliferation index, having a median 64.49 compared 52.86 negative 0.015). Neoadjuvant immunotherapy led lower mean cancer burden (0.95 2.55, 0.002) chemotherapy alone. Higher levels (≥50%) associated better outcomes, showing RCB score 1.60 versus 3.16 0.022). HER2-negative had prevalence favorable pathological response (54.5%) HER2-low (25%, 0.048), because strong high proliferative index. Conclusions: conclusion, shows significant discordance post-treatment, highlighting need routine testing further research predictive biomarkers.

Language: Английский

Citations

1
Analyzing Neoadjuvant Chemotherapy Effects in HER2-Low Breast Cancer: Real World Data DOI Open Access
Marcelo Antonini, André Mattar, Fernanda Grace Bauk Richter

et al.

Cureus, Journal Year: 2024, Volume and Issue: unknown

Published: May 4, 2024

Purpose: Neoadjuvant chemotherapy (NAC) can be used as upfront therapy in aggressive breast cancer (BC). human epidermal growth factor receptor 2 (HER2)-low BC, defined tumors scoring +1 or +2 on immunohistochemistry without HER2 gene amplification by situ hybridization, lacks information real-world data (RWD) outcomes, especially the NAC setting. This subgroup, which does not reach positive criteria due to its lower expression, represents a distinct clinical category potentially requiring tailored therapeutic approaches. Study objective: The objective of this study is characterize patients with BC HER2-low status who received Brazilian public reference center for female and key outcomes such pathological complete response (pCR), overall survival (OS), metastasis-free (MFS). Methods: A retrospective cohort based large database from Brazil. Patients that NAC, diagnosed between 2011 2020, were included if they presented (defined hybridization) had outcomes. Clinical demographic collected, age, menopausal status, Ki-67, hormone expression others. Key comprised pCR ypT0/TIs/ypN0), survival, Survival analyses conducted through semiparametric Kaplan-Meier method assess OS MFS considering diagnosis index date. Results: Overall, 297 eligible 141 after matching definition. was seen 18 out (12.7%). median 8.2 years, 2.7 years. 83.4% non-pCR 58.1%; DFS 55.5% 40.6%. Conclusion: gives updated insights pCR, OS, women exposed NAC.

Language: Английский

Citations

0
Application Value of Music Therapy in Improving the Emotional State and Quality of Life of Hospitalized Patients with Breast Cancer: Retrospective Study DOI Creative Commons

Juan Guo,

Zhongzhen Yu,

Xinping Xiao

et al.

Noise and Health, Journal Year: 2024, Volume and Issue: 26(122), P. 357 - 362

Published: July 1, 2024

Objective: This study aimed to apply music therapy as a clinical treatment for patients with breast cancer (BC) experiencing mild or moderate depression during hospitalization and observe any improvements in their quality of life. Methods: A total 102 who had mild-to-moderate depression, were diagnosed BC, admitted our hospital from October 2022 2023 selected the subjects retrospective analysis. According participation short-term therapy, they divided into control group (routine nursing n = 45) an observation + 57). Self-rating (SDS) scale functional assessment therapy-breast (FACT-B) Chinese version 4.0 scores patient satisfaction after compared between two groups. Results: After treatment, SDS FACT-B significantly better than those ( P < 0.001). The was higher 0.05). Conclusion: Music is highly safe method improve life BC. It also provides simple convenient nondrug broad application prospects.

Language: Английский

Citations

0